| Literature DB >> 35160292 |
Ragna Stalsberg1, Gro Falkenér Bertheussen2,3, Harriet Børset4, Simon Nørskov Thomsen5, Anders Husøy6, Vidar Gordon Flote7, Inger Thune7,8, Steinar Lundgren4,9.
Abstract
Exercise could reduce the side-effects of adjuvant breast cancer treatment; however, socio-demographic, health, and intervention conditions may affect patients' adherence to interventions. This study aimed to examine adherence to a 12-month outdoor post-surgery exercise program among newly diagnosed breast cancer patients during adjuvant treatment, and to identify socio-demographic and health-related predictors. In total, 47 women with invasive breast cancer stage I-II or ductal/lobular carcinoma grade 3 were included pre-surgery and randomized two weeks post-surgery to exercise (2 × 60 min/week). Patient characteristics (body-mass index (BMI), socioeconomic status, comorbidity, physical activity, and maximal oxygen uptake (VO2max)) were recorded pre-surgery. Correlations between adherence and patient characteristics and statistics for between-group differences were performed. The mean age was 54.2 years, mean BMI 27.8 kg/m2, and 54.2% received chemotherapy. Completers had a mean adherence of 81%, independent of season. Withdrawals (23%) occurred after a mean of 6.5 weeks (0-24 weeks), they were suggestively older, had lower socioeconomic status and pre-surgery VO2max, and higher BMI. Household income was significantly lower among withdrawals. There were insignificant correlations between adherence and health conditions. High adherence is achievable in a Nordic outdoor physical exercise program in breast cancer patients during adjuvant treatment, including chemotherapy. Additional studies are needed to clarify follow-up needs in some groups.Entities:
Keywords: adherence; breast cancer; outdoors intervention; physical activity; sociodemographic; withdrawal
Year: 2022 PMID: 35160292 PMCID: PMC8836448 DOI: 10.3390/jcm11030843
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flowchart of participants through the study.
Baseline characteristics of patients randomized to exercise intervention (N = 47, n = 36 vs. n = 11).
| Patient Characteristics at Baseline | |||
|---|---|---|---|
| Age | 54.2 (10.1) | 53.0 (9.8) | ≤55 years; >55 years: 0.427 c |
| Education | n.a. | ||
| | 12 (25.5) | 8 (22.2) | |
|
| 14 (29.8) | 14 (33.3) | |
|
| 13 (27.7) | 9 (19.4) | |
|
| 8 (17.1) | 5 (13.8) | |
| Occupation | n.a. | ||
|
| 7 (14.9) | 5 (13.9) | |
|
| 6 (12.8) | 4 (11.1) | |
|
| 13 (27.7) | 11 (30.6) | |
|
| 9 (19.1) | 9 (25.0) | |
|
| 6 (12.8) | 4 (11.1) | |
|
| 5 (10.6) | 2 (5.6) | |
| Household income a | 0.005 *c | ||
|
| 13 (27.7) | 10 (27.8) | |
|
| 17 (36.2) | 16 (44.4) | |
|
| 17 (36.2) | 10 (27.8) | |
| Currently smoking | 7 (14.9) | n.a. | |
| Number of comorbidities | 1.2 (1.2) | 5 (13.9) | n.a. |
| Occupational physical activity b | 0.909 c | ||
|
| 22 (46.8) | 18 (50.0) | |
|
| 8 (17.0) | 7 (19.4) | |
|
| 10 (21.2) | 8 (22.2) | |
| Leisure time physical activity (min/year) b | 8477 (6419) | 7710 (5615) | 0.269 d |
| BMI, kg/m2 | 27.8 (5.5) | 27.3 (5.2) | 0.279d |
| VO2max mL × kg−1 × min−1 | 28.4 (6.4) | 29.7 (5.4) | 0.010 *,e |
| Tumour characteristics | N (%) | N (%) | |
| Histology | 0.674 c | ||
|
| 44 (93.7) | 34 (94.6) | |
|
| 3 (6.4) | 2 (5.6) | |
| Pathologic tumour size, mm | 0.810 c | ||
|
| 10 (21.3) | 7 (19.4) | |
|
| 25 (53.2) | 20 (55.6) | |
|
| 12 (25.5) | 9 (25.0) | |
| Grade | 0.630 c | ||
|
| 11 (23.4) | 8 (22.2) | |
|
| 19 (40.4) | 16 (44.4) | |
|
| 14 (29.8) | 10 (27.8) | |
|
| 3 (6.4) | 2 (5.6) | |
| Lymph node involved | 0.336 c | ||
|
| 33 (70.2) | 24 (66.7) | |
|
| 13 (27.7) | 11 (30.6) | |
|
| 1 (2.1) | 1 (2.8) | |
| ER/PgR status | 0.059 c | ||
|
| 41 (87.2) | 33 (91.7) | |
|
| 3 (6.4) | 1 (2.8) | |
|
| 3 (6.4) | 2 (5.6) | |
| HER 2 status | 0.172 c | ||
|
| 11 (23.4) | 10 (27.8) | |
|
| 34 (72.3) | 24 (66.7) | |
|
| 2 (4.3) | 2 (5.6) | |
| Treatment | N (%) | N (%) | |
| Surgery (mastectomy/BCS) | 14 (29.8)/33 (70.2) | 12 (33.3)/24 (66.7) | 0.336 c |
| Endocrine therapy | 30 (63.8) | 26 (72.2) | 0.030 *,c |
| Chemotherapy * | 25 (53.2) | 21 (58.3) | 0.201 c |
| Trastuzumab | 9 (19.1) | 9 (25.0) | 0.065 c |
| Radiotherapy | 36 (76.6) | 27 (75.0) | 0.640 c |
| Zolendronic acid | 17 (36.2) | 14 (38.9) | n.a. |
a High: NOK ≥ 1,000,000; Medium: NOK 600,000-999,999; Low: NOK <350,000–599,999 b Numbers may vary due to missing information. c Chi-square test, d Mann–Whitney U-test, e T-test. * Statistically significant, α = 0.05. Abbreviations: IC, invasive carcinoma; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epithelial receptor; IORT, intraoperative radiotherapy; ND, not done; BMI, body mass index (kg/m2); n.a., not assessed. * fluorouracil, epirubicine and cyclophosphamide (FEC) or epirubicine and cyclophosphamide (EC), every third week for 4–6 cycles, or 4 cycles of either FEC or EC, and/or Taxanes (every third or weekly) for 12 weeks.
Figure 2Attendance from the start throughout the last group exercise session attended. Orange plots indicate attendances. Each row represents one patient. Grey rectangle indicates the group average participation period of the withdrawals (in order to avoid patient recognition).
Figure 3Total attendance to group exercise sessions (%). Left: exercise group; completers (n = 36); right: exercise group; total (n = 47).
Correlations between sociodemographic and clinical characteristics of the patients, by adherence to supervised group exercise program (60 min × 2/week)—overall, and stratified by four periods (1st, the 2nd, the 3rd, and the 4th quarter).
| Variable | 1st Quarter | 2nd Quarter | 3rd Quarter | 4th Quarter | 80 Group Sessions |
|---|---|---|---|---|---|
| Completers in exercise group (n = 36) | |||||
| a
| 0.093 | −0.036 | −0.088 | −0.205 | −0.195 |
| a
| −0.026 | −0.062 | −0.031 | 0.042 | 0.067 |
| a
| −0.206 | −0.179 | −0.103 | −0.126 | −0.106 |
| a
| 0.226 | 0.150 | 0.039 | 0.090 | 0.091 |
| a
| 0.247 | 0.158 | 0.070 | 0.045 | 0.059 |
| b
| 0.210 | 0.236 | 0.341 * | 0.366 * | 0.369* |
| b
| −0.229 | −0.236 | −0.155 | −0.117 | −0.085 |
| b
| −0.259 | −0.110 | −0.154 | −0.052 | −0.067 |
| a
| −0.168 | −0.116 | −0.050 | 0.015 | −0.004 |
| Withdrawals included (n = 47) | |||||
| a
| 0.024 | −0.042 | −0.054 | −0.120 | −0.114 |
| a
| 0.051 | 0.002 | −0.020 | −0.014 | 0.027 |
| a
| −0.082 | −0.036 | 0.054 | 0.049 | 0.061 |
| a
| 0.245 | 0.173 | 0.054 | 0.081 | 0.080 |
| a
| 0.008 | −0.078 | −0.156 | −0.171 | −0.159 |
| b
| −0.143 | −0.150 | −0.119 | −0.109 | −0.103 |
| b
| −0.098 | −0.129 | −0.139 | −0.148 | −0.139 |
| b
| 0.038 | 0.163 | 0.226 | 0.287 | 0.283 |
| a
| −0.237 | −0.052 | −0.207 | −0.172 | −0.132 |
a Tau-b; b Pearson’s r.* Statistically significant before a Holm-Bonferroni correction, but not after (p > 0.05).
Mean rank adherence to group exercise after the 1st, after the 2nd, after the 3rd, and after the 4th intervention quarter (n = 36 and n = 47). H- and U-statistics for Mann–Whitney U- and Kruskal–Wallis’ tests, respectively (p-value).
| 1st Quarter | 2nd Quarter | 3rd Quarter | 4th Quarter | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable |
| Mean Rank | U/H | Mean Rank | U/H | Mean Rank | U/H | Mean Rank | U/H |
| Education ( | |||||||||
| <College degree | 14 | 17.32 | 170.5 (0.59) a | 17.93 | 162 | 19.25 | 143.5 | 20.50 | 126 (0.37) a |
| ≥College degree | 22 | 19.25 | 18.86 | 18.02 | 17.23 | ||||
| Education ( | |||||||||
| <College degree | 21 | 22.19 | 311 | 22.21 | 310.5 | 22.57 | 303 | 23.33 | 287 |
| ≥College degree | 26 | 25.46 | 25.44 | 25.15 | 24.54 | ||||
| Occupation | |||||||||
| Blue-collar | 15 | 16.17 | 122.5 (0.36) a | 16.0 | 120 | 16.53 | 128 | 17.47 | 142 (0.80) a |
| White-collar | 20 | 19.38 | 19.5 | 19.10 | 18.40 | ||||
| Occupation | |||||||||
| Blue-collar | 19 | 21.97 | 227.5 | 21.79 | 224.0 | 22.16 | 231 | 23.08 | 245 |
| White-collar | 26 | 23.75 | 23.88 | 23.62 | 22.89 | ||||
| Income ( | |||||||||
| Low | 10 | 21.65 | 2.342 (0.31) b | 22.00 | 1.695 | 21.65 | 1.424 | 22.30 | 1.956 |
| Medium | 16 | 18.97 | 17.81 | 16.59 | 16.41 | ||||
| High | 10 | 14.60 | 16.10 | 18.40 | 18.05 | ||||
| Income ( | |||||||||
| Low | 17 | 24.15 | 2.165 | 23.71 | 1.211 | 22.56 | 0.560 | 22.74 | 0.526 |
| Medium | 17 | 27.12 | 26.56 | 25.94 | 25.91 | ||||
| High | 13 | 19.73 | 21.04 | 23.35 | 23.15 | ||||
| Age ( | |||||||||
| ≤55years | 19 | 16.50 | 199.5 | 16.97 | 190.5 | 15.87 | 211.5 | 15.50 | 218.5 |
| >55 years | 17 | 20.74 | 20.21 | 21.44 | 21.85 | ||||
| Age ( | |||||||||
| ≤55years | 23 | 24.61 | 262 | 24.89 | 255.5 | 23.61 | 285 | 23.26 | 293 |
| >55 years | 24 | 23.42 | 23.15 | 24.38 | 24.71 | ||||
| OPA-level c
| |||||||||
| Active | 15 | 19.67 | 175.0 | 18.33 | 155.0 | 16.93 | 134 | 17.93 | 149 |
| Sedentary | 18 | 14.78 | 15.89 | 17.06 | 16.22 | ||||
| OPA-level c
| |||||||||
| Active | 18 | 23.97 | 206.5 | 22.61 | 236 | 20.92 | 205.5 | 21.64 | 218.5 |
| Sedentary | 22 | 17.66 | 18.71 | 20.16 | 19.57 | ||||
| LTPA-level d
| |||||||||
| >150 min/week | 13 | 20.08 | 170 | 19.15 | 158 | 17.88 | 141.5 | 17.08 | 131 |
| <150 min/week | 19 | 14.05 | 14.68 | 15.55 | 16.11 | ||||
| LTPA-level d
| |||||||||
| >150 min/week | 18 | 22.22 | 229 | 21.42 | 214.5 | 20.86 | 204.5 | 20.31 | 194.5 |
| <150 min/week | 23 | 20.04 | 20.67 | 21.11 | 21.54 | ||||
a Mann–Whitney U test; b Kruskal–Wallis’ test; c Level of daily occupational physical activity (OPA); d Minutes of leisure-time physical activity (LTPA)/week, on average, during the last 12 months.